Glioblastoma (GBM) is the most common malignant brain tumor. Radiotherapy post surgical resection remained the mainstay of the management of GBM for decades until the addition of temozolomide was shown to prolong the median overall survival (OS) by 2.5 months to 14.6 months in 2005. Infiltrative growth to surrounding normal brain tissue and cooption of vascular niches, peripheral microvasuclar hyperplasia, and central hypoxic regions with pseudopalisading necrosis are characteristics of GBM and are causally linked to their exceptional radio-and chemo-resistant phenotype. An intratumoral hierarchy is postulated consisting of tumor stem cells in the apex with high DNA-repair proficiency resisting radiotherapy. It is conceivable that the stem cell property is more dynamic than originally anticipated. Niche effects such as exposure to hypoxia and intercellular communication in proximities to endothelial or bone marrow-derived cells (BMDC), for example, may activate such "stem cell" programs. GBM are exceptionally stroma-rich tumors and may consist of more than 70% stroma components, such as microglia and BMDC. It becomes increasingly apparent that treatment of GBM needs to integrate therapies targeting all above-mentioned distinct pathophysiological features. Accordingly, recent approaches in GBM therapy include inhibition of invasion (e.g., integrin, EGFR, CD95, and mTOR inhibition), antiangiogenesis and stroma modulators (TGFbeta, VEGF, angiopoetin, cMET inhibitors) and activation of immune response (vaccination and blockage of negative co-stimulatory signals). In addition, high LET-radiotherapy, for example with carbon ions, is postulated to ablate tumor stem cell and hypoxic cells more efficiently as compared with conventional low-LET photon irradiation. We discuss current key concepts, their limitations, and potentials to improve the outcome in this rapidly progressive and devastating disease. G lioblastoma (GBM) is the most common malignant primary brain tumor in adults. Since the 1970s, radiotherapy together with surgery has constituted the cornerstone in multimodal management of patients with GBM. 1 In 2005, the addition of alkylating agent temozolomide chemotherapy to radiotherapy was shown to prolong the median overall survival (OS) of newly-diagnosed patients with GBM by 2.5 months (from 12.1 to 14.6 months). 2 Therefore, this regimen is considered current standard in management of this devastating disease. A recent phase III trial investigated the effect of dose escalation of maintenance temozolomide chemotherapy from standard (150 -200 mg/m 2 days 1 to 5 of a 28-day cycle) to dose-dense temozolomide (administered at 75-100 mg/m 2 for 21 consecutive days of a 28-day cycle). Interestingly, the median OS was 16.6 months in standard-versus 14.9 months in the dose-dense temozolomide arm, respectively, and no statistically signifıcant difference was observed between arms (hazard ratio [HR] 1.03; p ϭ 0.63). Likewise, previous radiotherapy dose escalation studies did not improve OS in GBM. 3 Toward improvement of GBM therapy, a better comprehension of distinct biology and mechanisms governing therapy resistance is needed. Histopathologic features distinguishing GBM from lower-grade astrocytomas include: (a) central necrotic foci with surrounding highly hypoxic cellular pseudopalisades that contribute via expression of angiogenic and extracellular matrix (ECM)-remodeling factors to the (b) microvascular hyperplasia, and (c) infıltra-tive growth in the tumor periphery. 1
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LOCAL RECURRENCE AS THE PREDOMINANT PATTERN OF THERAPY FAILURE
In contrast to most other solid tumors where systemic tumor progression often limits the effıcacy of local treatments such as surgery and radiotherapy, in GBM, the predominant pattern of therapy failure is the development and rapid progression of local recurrences. Analysis of the GBM recurrence pattern post surgery and radiotherapy indicated that the vast majority of all recurrent tumors are localized in the high-dose radiation fıeld. Based on the volume of the recurrent tumor localizing within the initial high-dose region of radiotherapy the term "central" recurrence (Ͼ95%), "in-fıeld" recurrence (Ͼ80%), "marginal" recurrence (between 20% and 80%) and "distant" recurrence were used. Although more than 91% of recurrences were central (78%) or in-fıeld (13%), respectively, only 9% were marginal, and no distant recurrences were found. 4 Later studies of recurrence pattern after radiochemotherapy confırm that more than 90% of recurrences are central. 5 The introduction of amino-acid positron emission tomography (PET) has fueled hopes that biologic imaging may guide radiation oncologists to better delineate the metabolically active tumor region. Consequently, dose escalation in these regions was postulated to increase local control and improve patients' survival. Indeed, encouraging improvements of OS were reported, for example, in radiotherapy of recurrent gliomas by integrating biologic imaging in treatment planning. 6 However, recent studies found only a detrimental effect of integrating the biologic target volumes on patients survival. 5, 7 Larger prospective trials are needed to confırm the effects of metabolic imaging in radiotherapy planning of GBM.
A CROSSTALK BETWEEN THE MOLECULAR DRIVERS OF GBM INVASION AND THERAPY RESISTANCE
Post resection of tumor bulk, only a few tumor cells infıltrat-ing surrounding normal tissue remain that survive irradiation doses up to 90Gy. This quickly raises the question whether the two processes of tumor invasion and therapy resistance are not interconnected. 8 In fact, invasive GBM cells were shown to gain tumor stem cell characteristics, activation of Akt signaling, and relative resistance to mTOR inhibition by rapamycing as compared with parental cells. 9 In line with these observations, experimental evidences are provided that mechanisms governing the invasive program may also render GBM cells resistance to radiotherapy. 10 The existence of such crosstalk between different dynamic pathways points toward the intratumoral heterogeneity and the lack of optimal experimental models to investigate the therapy response of this distinct invasive population rather than the tumor bulk in vivo. In this context, at least two pathways have been forwarded into the clinical evaluation phase and are briefly mentioned here. Inhibition of CD95L/CD95 signaling was shown to reduce glioma cell invasion and tumor stem cell characteristic 11 and is currently investigated in combination with radiotherapy in GBM (phase II trial: NCT01071837). Integrin antagonists were shown to effıciently inhibit tumor invasion and enhance the effect of radiotherapy in preclinical glioma models. 12 In contrast to promising phase II data, the fırst generation integrin antagonist cilgengitide consisting of a cyclic pentapeptide harboring the integrin binding motif (RGD amino acid sequence) did not alter the infıltrative tumor growth pattern and failed to improve OS in combination with radiotherapy and temozolomide in newly diagnosed GBM (Centric NCT00689221 phase III trial 13 ).
RECURRENT-GLIOMA-INITIATING CELLS (R-GIC)
More than a decade has passed since the introduction of the modern cancer stem cell theory in solid tumors, and still controversies exist on defınition, proper cellular, and molecular characterization of this subpopulation in different tumor entities. The original model suggested a static intratumoral hierarchy, with a cancer stem cell population in the apex exhibiting high self-renewal and DNA double-strand breakage (DSB) repair capacities that consequently leads to their inherent resistance to conventional cancer therapies, such as radiotherapy. 14 The key implication for therapy was that eradication of only these cells, and not the entire tumor bulk, was required to prevent tumor recurrence or regress tumors. Interestingly, others have shown that glioma stem cells do not necessarily present a higher radioresistance phenotype as compared with, for example, classical human GBM cell lines. 15 It is increasingly apparent that intratumoral hierarchies are more dynamic, and acquisition of tumor stem cell traits could be influenced by a number of niche factors, such as signalings induced by intratumoral hypoxia, or as mentioned earlier, as a result of transition of tumor cells into the invasive state, or via intercellular communication in the tumorstroma interface for example, glioma-microglia, glioma-BMDC, or glioma-micrvascular endothelium. 16 Based on the premise that recurrent GBM must be generated from few residual tumor cells post surgery, the term recurrent gliomainitiating cells (R-GIC) seems to better describe this population. Novel tools are needed to longitudinally trace the fate of the R-GIC population in vivo and to better understand the temporal dynamic and molecular mechanisms under-
KEY POINTS
⅐ Local recurrence, within 2-3 cm of the presurgical, initial tumor margin is the predominant pattern of failure following radiochemotherapy of GBM. Neither escalation of the radiation dose nor intensified chemotherapy, for example dose-dense temozolomide, has improved the outcome. ⅐ Multimodal imaging, integrating tumor metabolism (e.g., aminoacid PET) with functional parameters (MRI), as well as molecular diagnostics are postulated to improve tumor delineation, predict therapy response, and assist in stratifying patients with GBM most benefiting from radiotherapy or combination regimens. However, statistically powered prospective trials are needed to provide a definitive proof for these concepts. ⅐ GBM invasion, arrested "dormant" residual tumor cell clones, and intratumoral hierarchy governed by so-called glioma stem cells with high DNA-repair proficiency are discussed among the key tumor-specific radioresistance mechanisms. ⅐ GBMs are exceptionally stroma-reach and angiogenic tumors; therefore, the tumor-stroma-vessel interface is increasingly recognized as a promising therapeutic target.
Whether the improved progression-free survival after adjuvant antiangiogenic therapy (bevacizumab) could be translated into prolonged survival will remain a therapeutic challenge. Additional trials are required to identify the best combination and sequence (concurrent, adjuvant, or at recurrence) of different therapy modalities. ⅐ High-LET irradiation with carbon ions offers theoretical advantageous over low-LET photon therapy in eradication of glioma stem cells and hypoxic tumor cells, which warrants further investigation.
lying their relative resistance to radiochemotherapy. Invariably, the low-cycling R-GICs population residing in surrounding tissue or coopting preexistent vessels will ultimately escape from their dormant state and switch to the angiogenic phenotype to grow exponentially and develop recurrent macroscopic tumors. Although the transcriptional consequence of this switch is well studied, and recruitment of BMDCs seems to play an important role in this process, the molecular determinants triggering the switch are still elusive. 17, 18 In addition to BMDC, a growing body of data indicate a pivotal role for glioma-microglia communication in GBM development and therapy refractoriness. In analogy to the role of tumor-associated macrophages (TAM, M1/2) and myofıbroblasts in modulating the niche of other solid tumors, microglias are involved in numerous processes reaching from immune modulation to ECM remodeling. 19 The intratumoral preponderance and multifaceted functions of microglia make them an attractive yet less-explored target for treatment of GBM. Together, gliomas may exhibit different sensitivities to conventional or targeted tumor/antiangiogenic therapies at different stages of their development starting from the residual invasive cells, to low-cycling dormant R-TIC state, to fast growing macroscopic recurrent tumor mass. To identify the best sequence of treatment, these temporal specifıcities of tumor-niche communication need to be better understood and considered, in particular, when multimodal trials are designed.
ANTIANGIOGENIC THERAPY
Angiogenesis is a prerequisite for all solid tumors to grow above ϳ1 mm 3 , therefore, the tumor microvessel endothelium has emerged as a critical target for cancer therapy. 1 Intriguingly, radiotherapy was shown to exert direct antiangiogenic effects. However, paracrine release of angiogenic growth factor by tumor/stroma and the corresponding upregulation of angiogenic receptors in the endothelium may represent a coordinated mechanism by which radiationinduced endothelial cell damage and apoptosis are effectively evaded. Consequently, it was shown that resensitzing tumor endothelium via blockage of these evasive proangiogenic mechanisms by, for example, inhibiting VEGF, bFGF, EGF, mTOR, PDGF, or integrin signaling enhances the antiangiogenic and antitumor effect of radiotherapy. 1,20 Some of these concepts have already been successfully translated in advanced phase II/III clinical trials.
Antiangiogenic therapy is effıcient in blocking exponential angiogenesis-dependent tumor growth, whereas disseminated invasive tumor cells co-opting pre-existing vessels could survive this type of therapy. Of note, the exponential growth of these microscopic tumor satellites that surround large vessels is still angiogenesis dependent. This provides a plausible explanation for the success of radiotherapy in reirradiation of relapsed radioresistant GBM derived from the R-GIC population. It was recently reported that augmented influx of CD11bϩ BMDC to the irradiated tumor bed via activation of the HIF1alpha-SDF-1/CXCR4 axis contribute to glioma relapse. In contrast to angiogenesis, that is, generation of new vessels from the local preexisting vessels, it was postulated that vasculogenesis mediated by differentiation of BMDC into new vessels govern tumor relapse after radiotherapy. 21 Observations in most other solid tumors contradict the relevance of BMDC-derived endothelial progenitors in revascularization of relapsed tumors post radiotherapy. 22 Undoubtedly, BMDC are playing a critical role in tumor therapy refractoriness, the switch of dormant tumors to angiogenic phenotype, and ultimately tumor relapse. Recent correlation of enhanced influx of myeloid cells in relapsed GBM specimens after antiangiogenesis and radiochemotherapy underscore the relevance of this stromal compartment in therapy referactoriness. 23 
ANTI-VEGF THERAPIES IN GBM
Among the most advanced concepts translated into the clinic is the inhibition of angiogenesis by the VEGF-neutralizing antibody bevacizumab. Two recent phase III trials revealed a signal for improved progression-free survival (PFS) after bevacizumab and radiochemotherapy in newly diagnosed patients with GBM. 24, 25 However, the benefıcial effects of adding bevacizumabs on PFS were not translated into a prolonged OS. Moreover, the studies produced diametral opposing results with regard to the endpoints neurotoxicity and general deterioration of patients' health status. Whereas RTOG-0825 reported more frequent decline in neurocognitive function and a worse quality of life in bevacizumab versus placebo arm, the AVAglio study group reported a longer conservation of the health-related quality of life and performance status ("deterioration-free-survival"), and lower glucocorticoid requirement in the bevacizumab arm. Therefore, further studies are required to clarify the effect of bevacizumab in concurrent and adjuvant settings in GBM. But, what could we still learn from these large randomized trials, and how could we design better rationally designed trials in the future? Does maintenance bevacizumab therapy lead to partial blockage of VEGF-dependent angiogenesis and consequently select for tumor cells that demonstrate a high degree of fıtness to survive the hypoxic conditions resulting from the impaired tumor perfusion? Does bevacizumab therapy select for tumor cells with an augmented capacity to invade the surrounding tissue and co-opt preexisting vessels that are less prone to anti-VEGF treatments? The exponential growth of these microscopic tumor satellites that surround large vessels is most likely still angiogenesis dependent. Therefore, why does anti-VEGF therapy not stop or at least delay the growth of macroscopic tumors out of these tumor satellites? The improved PFS observed in these trials is in line with current understanding of the mechanism of action of VEGF-targeting antiangiogenic therapy. We need to identify the evolutionary landscape underlying tumor referactoriness to anti-VEGF therapy and precisely target those mechanisms to produce more enduring responses. For example, gliomaevasive mechanisms might be circumvented by multimodal therapies more effıciently targeting hypoxic tumor cells, such as carbon radiotherapy (see later in this article), preventing tumor invasion, and compensatory pro-angiogenic mechanisms to single-agent anti-VEGF therapy. 1 However, if proper salvage therapies are not yet available, may the generation of hypoxic and invasive tumors by anti-VEGF therapy not impair the effıcacy of reirradiation of relapsed tumors? Preliminary data suggest promising outcomes when bevacizumab is added to reirradiation in the recurrent setting in antiangiogenesis-naïve GBM. 26, 27 RTOG-1205 will provide more defınitive evidence for this alternative strategy.
Another valuable result from the RTOG-0825 study is that no correlation was found between the 9-gene-expression signature and the clinical outcome. The gene-expression signature was a composite of most robustly detected genes in FFPE material identifıed after integration of four independent microarray datasets. 28 These data indicate that the gene expression-based diagnostic is still not ready for the prime time in GBM. Perhaps microRNAs or DNA-methylation patterns, which are more robust against processing bias introduced by FFPE conservation, may provide a better alternative for identifıcation of a biomarker. Another source for bias might be the relatively heterogeneous treatments of patients studied in large cohorts such as The Cancer Genome Atlas (TCGA) as compared with the RTOG-0825. Therefore, caution is warranted in interpretation and classifıcation of GBM into, for example, proneural, classical, and mesenchymal subtypes solely based on matched clustering of gene expression. Additional prospective trials are needed to validate the value of these classifıcations. Likewise, the predictive value of O 6 -methylguanine-DNA methyltransferase (MGMT) promoter methylation status to stratify patients most benefıting from radiochemotherapy is, at least within the radiotherapy community, still controversy debated. 29 Whereas the biologic basis for impaired DNA repair is given for alkylating agents like temozolomide, it is conceivable that epigenetic silencing of MGMT does not chiefly affect the nonhomologous end joining (NHEJ) relevant to radiation-induced DSB. Interestingly, dose-dense temozolomide treatment added no benefıt to PFS and OS as compared with the standardtreatment arm, regardless of the MGMT methylation status. 3 However, the MGMT status correlated well with all endpoints irrespective of temozolomide dose used, suggesting a dose threshold for combined effect of the alkylating agent with radiotherapy. In conclusion, large prospective trials provide an excellent platform to validate diagnostic markers. In contrast to temozolomide, specifıc and robust predictors of radiotherapy response are urgently needed. In addition to molecular markers, integration of longitudinal measures of, for example, tumor perfusion, vasuclarity, permeability, and cellularity via modern diffusion weighted (DWI) and dynamic contrast-enhanced (DCE) MRI imaging may facilitate the identifıcation of those patients that most probably benefıt from combined antiangiogenics and radiochemotherapy. 30 
RADIOTHERAPY WITH CARBON IONS
The emergence of heavy ion radiotherapy using carbon ions and raster scanning techniques constitutes a landmark development in the fıeld of high-precision radiotherapy. 31 In vitro studies in different glioma tumor cell lines suggest a higher cell killing effect of carbon as compared with conventional photon irradiation. 32 Carbon ions are less dependent on the oxygen enhancement ratio (OER) as compared with conventional photon irradiation and could therefore also eradicate hypoxic GBM cells, for example, post-maintenance antiangiogenic therapy. Induction of apoptosis, autophagy, and cellular senescence are among other postulated mechanisms underlying the enhanced glioma cell kill by carbon irradiation. 33, 34 Carbon irradiation was shown to inhibit glioma migration via decreased expression of integrins. 35 Moreover, it was recently postulated that carbon ions may overcome the inherent radioresistance of cancer stem cells. 36 Experimental studies in colorectal-and pancreatic-cancer models support this hypothesis. 37, 38 In analogy to photon irradiation, recent data indicate benefıcial effects of chemoradiation, in particular, temozolomide and paclitaxel, in combination with carbon irradiation in treatment of GBM. 32, 39 In a preliminary phase I/II clinical trial, the survival of patients with glioblastoma treated with carbon radiotherapy increased in a dose-dependent manner. 40 Together, carbon radiotherapy may open a new venue in treatment of these stroma-rich and radioresistant tumors with still devastating clinical outcome and unmet medical need for development of novel therapy strategies.
